Engflag

Letrogen

Quick links to important sections

Letrogen

There is no image.

Method of action: Antitumour, Endocrine Therapy, Inhibitor Of Estrogen Synthesis, Inhibitory Synthesis Of Estrogens

Treatment option: Cancer, Breast Cancer, Chemotherapy, Surgery

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Letrogen

Letrogen is a branded prescription medication whose active substance is Letrozole, which is classified as a third-generation nonsteroidal Aromatase Inhibitor (AI). This formulation is clinically recognized for its high potency and specific action in anti-estrogen therapy.

Property Description
Active Ingredient Letrozole (C17H11N5)
Form Oral tablet (e.g., film-coated tablet)
Pharmacological Class Aromatase Inhibitor (AI), Antineoplastic Agent
Common Use Hormonal therapy requiring systemic estrogen suppression (general purpose)
Origin Synthetic, Nonsteroidal compound

What is Letrogen and What Class Does it Belong To?

Letrogen is the trade name for the pharmaceutical substance Letrozole, which belongs to the class of Antineoplastic Agents. More specifically, it is categorized as a third-generation Aromatase Inhibitor, a highly selective and potent drug designed to prevent hormone production. This classification highlights the drug's specialized role in therapeutic strategies that aim for powerful systemic estrogen suppression. The drug is a synthetic, nonsteroidal compound, meaning its structure and action are chemically engineered to target the hormone production process directly.

Composition, Origin, and Form

The medication is supplied as a single-ingredient product delivered as an oral tablet for oral administration. The tablets contain the active substance, Letrozole, along with standard solid pharmaceutical excipients necessary for stability and absorption. The substance is a type of hormone therapy. The formulation demonstrates high bioavailability, and this oral form ensures the necessary systemic effect, allowing the compound to circulate throughout the body and target the enzyme responsible for estrogen production in peripheral tissues.

What is the General Purpose of an Aromatase Inhibitor?

The general therapeutic purpose of a medicine in the Aromatase Inhibitor class is to achieve profound estrogen suppression. This is accomplished by blocking the activity of the aromatase enzyme (CYP19A1), which converts androgens into estrogen outside the ovaries. Third-generation AIs like Letrozole are often utilized for certain therapeutic needs in postmenopausal women. This drug represents a modern method for antiestrogen therapy by reducing the circulating availability of the hormone.

Regulatory References

  1. NCI Dictionary of Cancer Terms: Aromatase Inhibitor

What side effects are possible with Letrogen?

Possible Side Effects and Safety Information

Letrogen (Letrozole) is associated with a range of adverse reactions primarily related to its mechanism of action, which reduces estrogen levels. All safety information is based on formal regulatory documents and clinical trials.

Classification Adverse Reactions (Examples)
Very Common (ge 10%) Hot flashes, arthralgia (joint pain), increased sweating (hyperhidrosis), fatigue (asthenia), dizziness, headache, edema, and hypercholesterolemia (high cholesterol).
Common (ge 1% - <10%) Nausea, vomiting, diarrhea, constipation, increased or decreased appetite, somnolence, depression, bone pain, musculoskeletal pain, alopecia (hair loss), rash, and hypertension.

Serious and Clinically Significant Risks

Official regulatory warnings highlight several significant safety concerns:

  • Bone Health: Use may cause decreases in Bone Mineral Density (BMD), leading to an increased risk of osteoporosis and bone fractures. Monitoring of BMD should be considered.
  • Cardiovascular: Significant increases in total cholesterol (hypercholesterolemia) are common, and monitoring of serum cholesterol is recommended.
  • Embryo-Fetal Toxicity: The drug is contraindicated in women who are or may become pregnant due to the risk of fetal harm, including spontaneous abortions and congenital birth defects. Females of reproductive potential must be advised to use effective contraception.

Restrictions and Special Populations

  • Contraindications: The medicine is strictly contraindicated in pregnant women and patients with known hypersensitivity to the active substance.
  • Hepatic Impairment: Dose reduction is generally recommended for patients with severe hepatic impairment (cirrhosis) as exposure to the drug is approximately doubled in this population.
  • Operating Machinery: Caution is advised when driving or operating machinery due to reported potential for fatigue, dizziness, and somnolence.

Overdose and Emergency Response

The official documentation concerning an overdose of the active substance Letrozole (Letrogen) indicates that clinical data in humans is limited. Regulatory records confirm the highest reported single ingestion of Letrozole was 62.5 mg, equivalent to twenty-five standard 2.5 mg tablets. Significantly, the official records state that no serious adverse reactions were reported in these known cases of overdose. This lack of defined serious manifestations means the regulatory authorities have formally stated that, due to the limited scope of available data, no firm recommendations for treatment can be made.

Despite the benign findings in reported cases, the regulatory instruction for emergency response is explicit: in the event that too much of this medicine is suspected to have been taken, the patient must contact a poison control center or emergency room at once. Management is primarily focused on general procedural and supportive measures. Officially described steps include administering supportive care and conducting frequent monitoring of vital signs to ensure physiological stability. Furthermore, the regulatory labeling notes that emesis (vomiting) could be induced as a procedural step, provided the patient is alert. This profile adheres to a conservative, precautionary approach, focusing on observation and supportive intervention as dictated by official prescribing information.

Therapeutic Uses of Letrogen

What Letrogen Treats: Main Uses and Benefits

Letrogen is a nonsteroidal agent used as a component of the treatment plan for specific hormone-sensitive conditions in postmenopausal women. The medication is indicated for distinct clinical uses relating to breast cancer.

Its therapeutic applications include:

  • Adjuvant treatment of hormone receptor-positive early breast cancer.
  • Extended adjuvant treatment in women who have completed five years of tamoxifen therapy.
  • First- or second-line management of advanced breast cancer in patients with hormone receptor-positive or unknown status.

This medicine provides support in managing disease activity and helps maintain the patient’s health trajectory as part of a comprehensive strategy. The goal of using this agent is to assist in the overall clinical management of the condition.

Quick Fact: Relief for Disease Activity Management

Eligibility and Restrictions for Use

The official regulatory eligibility profile for Letrogen is strictly defined by hormonal status and specific contraindications. Use is permitted only for postmenopausal women whose endocrine status has been clearly established.

Contraindications and Restrictions

The medicine is contraindicated and must not be used by several populations, including women who are premenopausal, pregnant, or breastfeeding. This exclusion is due to regulatory concerns regarding fetal risk and unknown effects on infants. Letrogen is also contraindicated for patients with a known hypersensitivity to the active substance or excipients, such as those with certain hereditary problems of galactose intolerance.

Regulatory documents also detail conditional restrictions:

  • Severe Hepatic Impairment (Child-Pugh C): Requires close supervision, and a formal dose reduction is recommended.
  • Severe Renal Impairment: Data are insufficient; the potential risk must be carefully considered.
  • Pediatric Patients: Use is not recommended, as safety and efficacy have not been established.
  • Osteoporosis Risk: Bone mineral density must be formally monitored prior to and during treatment.

What should I know about interactions with other medicines?

Letrogen Interactions with other medicines and products

The official regulatory profile for Letrogen (Letrozole) documents interaction patterns centered on pharmacokinetic (PK) changes and antagonistic pharmacodynamic (PD) effects.

Metabolic Enzyme Interactions

Letrozole is processed by the metabolic enzymes CYP3A4 and CYP2A6. Consequently, co-administration with potent inhibitors of CYP3A4 and CYP2A6 is officially documented to increase Letrozole exposure (Cmax and AUC). Conversely, when co-administered with Tamoxifen (or other antiestrogens), the result is a documented reduction in Letrozole plasma concentrations. Letrozole itself acts as a mild-to-moderate inhibitor of CYP2A6 and a mild inhibitor of CYP2C19, which can lead to increased exposure of co-administered medicines that are substrates for these specific enzymes.

Pharmacodynamic and Food Restrictions

The co-administration of estrogen-containing medicines, including hormone replacement therapy, is classified as a critical antagonistic pharmacodynamic interaction because it is documented to negate the anti-estrogen action of Letrozole. The official labeling confirms that food does not significantly affect the extent of Letrozole absorption; therefore, administration timing relative to meals is not a required restriction.

Mechanism of Action

Core Mechanism: How Letrogen Works

Letrogen's active ingredient, Letrozole, acts as a competitive inhibitor that targets the Aromatase Enzyme ( CYP19 A1). This enzyme is crucial for the rate-limiting step in estrogen production, converting precursor androgens into the hormones estrone and estradiol. By reversibly binding to the enzyme's active site, Letrozole physically blocks this conversion process.

The result of this selective molecular blockade is an interruption of the estrogen biosynthesis pathway. This action leads to a systemic decrease in circulating estrogen levels, creating a state of estrogen deprivation throughout the body. The mechanism is characterized by its selective action, minimizing significant interference with other steroidogenic pathways, such as those producing cortisol or aldosterone.

The functional capacity of this mechanism is constrained by the physiological context, as it is functionally overridden when the ovaries are active and produce high levels of estrogen. Furthermore, the mechanism can be limited over the long term by acquired resistance, where cells activate alternative growth signaling pathways (like PI3 K/ Akt), thus bypassing the dependence on the now-suppressed estrogen axis.

Dosage and Administration Information

How to Use Letrogen

The administration of Letrogen (Letrozole) follows specific instructions which define the standardized approach to its use. This section strictly describes the official dosing and schedule patterns and does not cover safety, efficacy, or mechanism of action.

Official Administration Guidelines

Instruction Detail
Route and Form The medication is for oral administration only, supplied as a 2.5 mg tablet.
Standard Dosing The prescribed dose for approved indications is a fixed 2.5 mg.
Frequency It is taken once daily (q.d.), and should be administered at approximately the same time each day.
Intake Condition The tablet may be taken with or without food.

Use Patterns and Adjustments

The duration of use is defined by the specific treatment plan. For adjuvant use, the typical course is a continuous therapy lasting up to five years. For advanced disease, treatment continues until there is evidence of tumor progression.

Dosing rules require no adjustment for older adults or patients with moderate renal impairment (creatinine clearance ge 10 mL/min). However, a dose reduction to 2.5 mg every other day is specified for patients diagnosed with severe hepatic impairment.

If a dose is missed, instructions advise taking it as soon as it is remembered. However, to prevent a double dose, the missed dose should be skipped if it is almost time for the next scheduled dose. The tablet must be swallowed whole.

Recent Clinical Evidence

Letrogen: Recent Clinical Evidence

This section summarizes the evidence from studies that have investigated the drug's activity and clinical findings in certain conditions.

Activity and Research Focus

Studies have investigated the drug's activity involving a specific enzyme. This activity has been the focus of research regarding inflammation and pain in conditions such as osteoarthritis and certain musculoskeletal disorders.

Clinical Evidence

Rheumatoid Arthritis (RA)

Studies have investigated the effects of the drug in adults with mild to moderate RA. Studies have investigated changes in mobility and joint stiffness measures in participants with mild to moderate rheumatoid arthritis (RA).

  • Trial Outcomes: A systematic review of five randomized controlled trials (RCTs) reported varying findings regarding long-term joint damage progression. Short-term studies (12 weeks) reported data on patient-reported disability measures.
  • Adverse Events Assessment: Research has included the assessment of adverse events in this population.

Acute Pain Investigation

Multiple Phase III clinical trials have investigated the drug's activity in acute post-surgical and trauma-related pain.

  • Key Findings: In a large-scale RCT, pain scores reported by participants who received the drug were compared to those who received placebo. Several small studies examined the time required for participants to report changes in pain.
  • Comparative Studies: Studies have included comparisons of the drug's activity to standard over-the-counter options.
  • Inflammation Activity: Some studies have also examined the drug's activity in inflammation.

Administration Research

Research has included the assessment of plasma concentration profiles following different study regimens.

  • Specific Populations: Studies have reported on the inclusion and exclusion criteria related to pre-existing liver conditions.

Key Studies & References

  1. Letrozole in Patients With Hepatopulmonary Syndrome - ClinicalTrials.gov (Used for example of exclusion criteria related to liver conditions in clinical trials)

Frequently Asked Questions (FAQ)

Common questions about Letrogen (FAQ)

Q: What is Letrogen used for?

Letrogen is a medication prescribed to treat certain types of breast cancer in postmenopausal women. It may also be used for other conditions as determined by your healthcare provider.

Q: How should I take Letrogen?

You should take Letrogen exactly as prescribed by your doctor. It is typically taken once a day, with or without food. Do not change your dose or stop taking the medication without consulting your healthcare provider.

Q: What are common side effects of Letrogen?

Common side effects may include hot flashes, joint pain, and fatigue. Report any persistent or bothersome side effects to your healthcare provider.

Q: Can Letrogen interact with other medicines?

Yes, Letrogen may interact with other medications, including certain hormone replacement therapies. It is essential to inform your doctor about all prescription, over-the-counter, and herbal supplements you are currently taking.

How should Letrogen be stored and disposed of?

The storage and disposal of Letrogen (Letrozole) must follow specific regulatory requirements to maintain product stability and safety.

Storage Conditions and Requirements

Scope Element Requirement from Regulatory Sources
Storage Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Excursions permitted 15 C to 30 C.
Protection Conditions Store away from excessive heat and moisture; keep the container tightly closed.
Container Rules Keep the medicine in the original container it was dispensed in.
Child Safety Store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Letrogen should be managed as pharmaceutical waste according to official guidelines.

  • Preferred Method: Disposal should primarily occur via a drug take-back program or authorized collection site when available.
  • Environmental Safety: Do not flush the tablets down the toilet or pour them down any drain unless the product's official labeling specifically instructs this method of disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBulgaria

Equivalent of Letrogen found in:

A-Z Index: